Quarterly ResultMay 5, 2026, 04:33 PM
Theriva Biologics FDA Aligns VCN-01 Phase 3 PDAC; Q1 Net Loss $2.0M
AI Summary
Theriva Biologics reported Q1 2026 financial results and provided a corporate update, highlighting significant progress in its clinical programs. The company aligned with the FDA on the Phase 3 trial design for VCN-01 in metastatic pancreatic ductal adenocarcinoma (PDAC) and initiated a compassionate use program for VCN-01 in retinoblastoma. As of March 31, 2026, Theriva Biologics had $14.4 million in cash and cash equivalents, providing a runway into Q1 2027, while reporting a net loss of $2.0 million for the quarter.
Key Highlights
- FDA aligned on VCN-01 Phase 3 trial design for metastatic pancreatic ductal adenocarcinoma (PDAC).
- VCN-01 compassionate use program initiated for retinoblastoma patients.
- Cash and cash equivalents totaled $14.4 million as of March 31, 2026.
- Cash runway is projected into Q1 2027.
- Net loss for Q1 2026 was $2.0 million, compared to $4.3 million in Q1 2025.
- Research and development expenses decreased 88% to $355,000 in Q1 2026.
- General and administrative expenses increased 43% to $2.1 million in Q1 2026.